ペランパネル服用中の薬剤抵抗性てんかん患者における睡眠への影響:観察研究
Fabio Lamanna1, Orazio Pardeo1, Diana Tilenni1
1Neurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
まとめ
ペランパネル(PER)は、難治性てんかん患者の睡眠の質と生活の質を改善した。PERは初回加療としてより高い有効性を示し、忍容性も良好であった。
科学分野:
- 神経学; てんかん学; 薬理学
背景:
- ペランパネル(PER)はAMPA受容体拮抗薬である。睡眠の質に対するPERの影響に関する研究は限られている。本研究では、難治性てんかん患者における睡眠へのPERの影響を評価した。
研究 の 目的:
- ペランパネルが睡眠の質に与える影響を評価する。日中の眠気と生活の質に対するペランパネルの効果を評価する。初回加療と後期加療としてのペランパネルの有効性を比較する。
主な方法:
- 難治性てんかん患者31例に、加療としてペランパネル(PER)を投与した。睡眠の質(PSQI)、日中の眠気(ESS)、生活の質(QOLIE-31)を評価した。有効性は発作減少により測定し、忍容性は有害事象により測定した。
主要な成果:
- 睡眠の質と日中の眠気はわずかに改善した。生活の質は軽度改善し、後期の加療患者では発作への懸念が著しく減少した。PERは忍容性が高く、初回加療として使用した場合に有効性が高いことが観察された(p=0.043)。
結論:
- ペランパネル(PER)は睡眠の質を維持し、生活の質を改善する可能性がある。PERは、薬剤抵抗性てんかんの初期加療として優れた有効性を示す。PERは、難治性てんかんの管理において忍容性の高い選択肢である。
関連する概念動画
Antiepileptic Drugs: Potassium Channel Activators
624
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
624
Sedatives and Hypnotics Drugs: Miscellaneous Agents
502
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
502
Antiepileptic Drugs: Glutamate Antagonists
884
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
884
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
630
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
630


